Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies

Growth Hormone and IGF Research

Volumn 25, Issue 2, 2015, Pages 59-65

  Stanley, Takara L ^a   Grinspoon, Steven K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular risk; Growth hormone; Growth hormone releasing hormone; Obesity; Visceral obesity

Indexed keywords

C REACTIVE PROTEIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; STAT5B PROTEIN; TESAMORELIN; TRIACYLGLYCEROL; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE;

ABDOMINAL OBESITY; ARTERIAL WALL THICKNESS; ARTHRALGIA; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; LIPOLYSIS; METABOLIC DISORDER; MYALGIA; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; HEALTH STATUS INDICATOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; GROWTH HORMONE-RELEASING HORMONE; HEALTH STATUS INDICATORS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRA-ABDOMINAL FAT; METABOLIC DISEASES; OBESITY; SIGNAL TRANSDUCTION;

EID: 84924943365     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2014.12.005     Document Type: Review

References (84)

1. Rosen T., Bengtsson B.-A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336(8710):285-288. (1990/8/4).
2. Rosen T., Eden S., Larson G., Wilhelmsen L., Bengtsson B.A. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. (Copenh) 1993, 128(2):67.
3. Colao A., Di Somma C., Rota F., Pivonello R., Savanelli M.C., Spiezia S., et al. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J. Clin. Endocrinol. Metab. Apr 2005, 90(4):2056-2062.
4. Colao A., Di Somma C., Spiezia S., Rota F., Pivonello R., Savastano S., et al. The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. J. Clin. Endocrinol. Metab. Jun 2006, 91(6):2191-2200.
5. Abs R., Feldt-Rasmussen U., Mattsson A.F., Monson J.P., Bengtsson B.A., Goth M.I., et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults-a KIMS database analysis. Eur. J. Endocrinol. Jul 2006, 155(1):79-90.
6. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Vance M.L. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. Jun 2011, 96(6):1587-1609.
7. Colao A., Di Somma C., Spiezia S., Savastano S., Rota F., Savanelli M.C., et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. Sep 2008, 93(9):3416-3424.
8. Miller K.K., Wexler T., Fazeli P., Gunnell L., Graham G.J., Beauregard C., et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J. Clin. Endocrinol. Metab. Feb 2010, 95(2):567-577.
9. Pasarica M., Zachwieja J.J., Dejonge L., Redman S., Smith S.R. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J. Clin. Endocrinol. Metab. Nov 2007, 92(11):4265-4270.
10. Jorgensen J.O., Pedersen S.A., Thuesen L., Jorgensen J., Ingemann-Hansen T., Skakkebaek N.E., et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet Jun 3 1989, 1(8649):1221-1225.
11. Jorgensen J.O., Vahl N., Hansen T.B., Thuesen L., Hagen C., Christiansen J.S. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin. Endocrinol. (Oxf) 1996 Dec, 45(6):681-688.
12. Bredella M.A., Gerweck A.V., Lin E., Landa M.G., Torriani M., Schoenfeld D.A., et al. Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity. J. Clin. Endocrinol. Metab. 2013, 98(9):3864-3872.
13. Johannsson G., Marin P., Lonn L., Ottosson M., Stenlof K., Bjorntorp P., et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 1997, 82(3):727-734.
14. Lo J., You S.M., Canavan B., Liebau J., Beltrani G., Koutkia P., et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA Aug 6 2008, 300(5):509-519.
15. Bredella M.A., Lin E., Brick D.J., Gerweck A.V., Harrington L.M., Torriani M., et al. Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. Eur. J. Endocrinol. 2012 Apr, 166(4):601-611.
16. Iranmanesh A., Lizarralde G., Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) ceretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 1991, 73:1081-1088.
17. Riedel M., Hoeft B., Blum W.F., von zur Muhlen A., Brabant G. Pulsatile growth hormone secretion in normal-weight and obese men: differential metabolic regulation during energy restriction. Metabolism May 1995, 44(5):605-610.
18. Ghigo E., Procopio M., Boffano G.M., Arvat E., Valente F., Maccario M., et al. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism 1992, 41(5):560-563.
19. Veldhuis J.D., Iranmanesh A., Ho K.K., Waters M.J., Johnson M.L., Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 1991, 72(1):51-59.
20. Kopelman P.G., Noonan K., Goulton R., Forrest A.J. Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycaemia in obesity. Clin. Endocrinol. (Oxf) Jul 1985, 23(1):87-94.
21. Williams T., Berelowitz M., Joffe S.N., Thorner M.O., Rivier J., Vale W., et al. Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N. Engl. J. Med. Nov 29 1984, 311(22):1403-1407.
22. Rasmussen M.H., Hvidberg A., Juul A., Main K.M., Gotfredsen A., Skakkebaek N.E., et al. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J. Clin. Endocrinol. Metab. Apr 1995, 80(4):1407-1415.
23. Vahl N., Jorgensen J.O., Skjaerbaek C., Veldhuis J.D., Orskov H., Christiansen J.S. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am. J. Physiol. Jun 1997, 272(6 Pt 1):E1108-E1116.
24. Miller K.K., Biller B.M., Lipman J.G., Bradwin G., Rifai N., Klibanski A. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J. Clin. Endocrinol. Metab. Feb 2005, 90(2):768-774.
25. Makimura H., Stanley T., Mun D., You S.M., Grinspoon S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. Nov 2008, 93(11):4254-4260.
26. Misra M., Bredella M.A., Tsai P., Mendes N., Miller K.K., Klibanski A. Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am. J. Physiol. Endocrinol. Metab. Aug 2008, 295(2):E385-E392.
27. Cornford A.S., Barkan A.L., Horowitz J.F. Rapid suppression of growth hormone concentration by overeating: potential mediation by hyperinsulinemia. J. Clin. Endocrinol. Metab. Mar 2011, 96(3):824-830.
28. Luque R.M., Kineman R.D. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology Jun 2006, 147(6):2754-2763.
29. Luque R.M., Gahete M.D., Valentine R.J., Kineman R.D. Examination of the direct effects of metabolic factors on somatotrope function in a non-human primate model, Papio anubis. J. Mol. Endocrinol. Aug 2006, 37(1):25-38.
30. Casanueva F.F., Villanueva L., Dieguez C., Diaz Y., Cabranes J.A., Szoke B., et al. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J. Clin. Endocrinol. Metab. Oct 1987, 65(4):634-642.
31. Cordido F., Peino R., Penalva A., Alvarez C.V., Casanueva F.F., Dieguez C. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J. Clin. Endocrinol. Metab. Mar 1996, 81(3):914-918.
32. Corneli G., Di Somma C., Baldelli R., Rovere S., Gasco V., Croce C.G., et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur. J. Endocrinol. Aug 2005, 153(2):257-264.
33. Utz A.L., Yamamoto A., Hemphill L., Miller K.K. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J. Clin. Endocrinol. Metab. Jul 2008, 93(7):2507-2514.
34. Di Somma C., Pivonello R., Pizza G., De Rosa A., Lombardi G., Colao A., et al. Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J. Endocrinol. Investig. Mar 2010, 33(3):171-177.
35. Makimura H., Stanley T., Mun D., Chen C., Wei J., Connelly J.M., et al. Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity. J. Clin. Endocrinol. Metab. Dec 2009, 94(12):5131-5138.
36. Carmichael J.D., Danoff A., Milani D., Roubenoff R., Lesser M.L., Livote E., et al. GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90. Clin. Endocrinol. (Oxf) Aug 2006, 65(2):169-177.
37. Makimura H., Feldpausch M.N., Stanley T.L., Sun N., Grinspoon S.K. Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size. Clin. Endocrinol. (Oxf) Feb 2012, 76(2):220-227.
38. Yusuf S., Hawken S., Ounpuu S., Bautista L., Franzosi M.G., Commerford P., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet Nov 5 2005, 366(9497):1640-1649.
39. Pischon T., Boeing H., Hoffmann K., Bergmann M., Schulze M.B., Overvad K., et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. Nov 13 2008, 359(20):2105-2120.
40. Ohashi N., Yamamoto H., Horiguchi J., Kitagawa T., Kunita E., Utsunomiya H., et al. Association between visceral adipose tissue area and coronary plaque morphology assessed by CT angiography. JACC Cardiovasc. Imaging Sep 2010, 3(9):908-917.
41. Liu J., Fox C.S., Hickson D., Bidulescu A., Carr J.J., Taylor H.A. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler. Thromb. Vasc. Biol. Nov 2011, 31(11):2715-2722.
42. Liu J., Fox C.S., Hickson D.A., May W.D., Hairston K.G., Carr J.J., et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J. Clin. Endocrinol. Metab. Dec 2010, 95(12):5419-5426.
43. McLaughlin T., Lamendola C., Liu A., Abbasi F. Preferential Fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J. Clin. Endocrinol. Metab. 2011, 96(11):E1756-E1760.
44. Manolopoulos K.N., Karpe F., Frayn K.N. Gluteofemoral body fat as a determinant of metabolic health. Int. J. Obes. (Lond.) Jun 2010, 34(6):949-959.
45. Neeland I.J., Turer A.T., Ayers C.R., Powell-Wiley T.M., Vega G.L., Farzaneh-Far R., et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA Sep 19 2012, 308(11):1150-1159.
46. Imai A., Komatsu S., Ohara T., Kamata T., Yoshida J., Miyaji K., et al. Visceral abdominal fat accumulation predicts the progression of noncalcified coronary plaque. Atherosclerosis Jun 2012, 222(2):524-529.
47. Kuk J.L., Katzmarzyk P.T., Nichaman M.Z., Church T.S., Blair S.N., Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) Feb 2006, 14(2):336-341.
48. Klein S., Fontana L., Young V.L., Coggan A.R., Kilo C., Patterson B.W., et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. Jun 17 2004, 350(25):2549-2557.
49. Mohammed B.S., Cohen S., Reeds D., Young V.L., Klein S. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease. Obesity (Silver Spring) Dec 2008, 16(12):2648-2651.
50. Thorne A., Lonnqvist F., Apelman J., Hellers G., Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. Relat. Metab. Disord. Feb 2002, 26(2):193-199.
51. Mekala K.C., Tritos N.A. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J. Clin. Endocrinol. Metab. Jan 2009, 94(1):130-137.
52. Richelsen B., Pedersen S.B., Borglum J.D., Moller-Pedersen T., Jorgensen J., Jorgensen J.O. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J. Physiol. Feb 1994, 266(2 Pt 1):E211-E216.
53. Hartman M.L., Faria A.C., Vance M.L., Johnson M.L., Thorner M.O., Veldhuis J.D. Temporal structure of in vivo growth hormone secretory events in humans. Am. J. Physiol. Jan 1991, 260(1 Pt 1):E101-E110.
54. Eden S. Age- and sex-related differences in episodic growth hormone secretion in the rat. Endocrinology Aug 1979, 105(2):555-560.
55. Mode A., Gustafsson J.A., Jansson J.O., Eden S., Isaksson O. Association between plasma level of growth hormone and sex differentiation of hepatic steroid metabolism in the rat. Endocrinology Nov 1982, 111(5):1692-1697.
56. Gustafsson J.A., Eden S., Eneroth P., Hokfelt T., Isaksson O., Jansson J.O., et al. Regulation of sexually dimorphic hepatic steroid metabolism by the somatostatin-growth hormone axis. J. Steroid Biochem. Jul 1983, 19(1B):691-698.
57. Waxman D.J., O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol. Endocrinol. Nov 2006, 20(11):2613-2629.
58. Gebert C.A., Park S.H., Waxman D.J. Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation. Mol. Endocrinol. Feb 1999, 13(2):213-227.
59. Jaffe C.A., Turgeon D.K., Lown K., Demott-Friberg R., Watkins P.B. Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am. J. Physiol. Endocrinol. Metab. Nov 2002, 283(5):E1008-E1015.
60. Surya S., Horowitz J.F., Goldenberg N., Sakharova A., Harber M., Cornford A.S., et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J. Clin. Endocrinol. Metab. Aug 2009, 94(8):2828-2834.
61. Faje A.T., Barkan A.L. Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J. Clin. Endocrinol. Metab. 2010 May, 95(5):2486-2491.
62. Cersosimo E., Danou F., Persson M., Miles J.M. Effects of pulsatile delivery of basal growth hormone on lipolysis in humans. Am. J. Physiol. Jul 1996, 271(1 Pt 1):E123-E126.
63. Duck S.C., Schwarz H.P., Costin G., Rapaport R., Arslanian S., Hayek A., et al. Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. J. Clin. Endocrinol. Metab. Oct 1992, 75(4):1115-1120.
64. Ross R.J., Rodda C., Tsagarakis S., Davies P.S., Grossman A., Rees L.H., et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet 1987, 1(8523):5-8.
65. Smith P.J., Brook C.G. Growth hormone releasing hormone or growth hormone treatment in growth hormone insufficiency?. Arch. Dis. Child. Jun 1988, 63(6):629-634.
66. Thorner M., Rochiccioli P., Colle M., Lanes R., Grunt J., Galazka A., et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy, Geref International Study Group. J. Clin. Endocrinol. Metab. 1996, 81(3):1189-1196.
67. Stanley T.L., Chen C.Y., Branch K.L., Makimura H., Grinspoon S.K. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab. Jan 2011, 96(1):150-158.
68. Rietschel P., Hadigan C., Corcoran C., Stanley T., Neubauer G., Gertner J., et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metab. Feb 2001, 86(2):504-510.
69. Koutkia P., Meininger G., Canavan B., Breu J., Grinspoon S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am. J. Physiol. Endocrinol. Metab. Feb 2004, 286(2):E296-E303.
70. Lo J., You S.M., Wei J., Canavan B., Grinspoon S. Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin. Endocrinol. (Oxf) 2009, 71(6):815-822.
71. Kotler D.P., Muurahainen N., Grunfeld C., Wanke C., Thompson M., Saag M., et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J. Acquir. Immune Defic. Syndr. Mar 1 2004, 35(3):239-252.
72. Kotler D.P., Muurahainen N., Grunfeld C., Wanke C., Thompson M., Saag M., et al. Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J. Acquir. Immune Defic. Syndr. Nov 1 2006, 43(3):378-380.
73. Grunfeld C., Thompson M., Brown S.J., Richmond G., Lee D., Muurahainen N., et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12week induction and 24-week maintenance therapy. J. Acquir. Immune Defic. Syndr. Jul 1 2007, 45(3):286-297.
74. Koutkia P., Canavan B., Breu J., Torriani M., Kissko J., Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA July 14 2004, 292(2):210-218. 10.1001/jama.292.2.210.
75. Falutz J., Allas S., Blot K., Potvin D., Kotler D., Somero M., et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N. Engl. J. Med. Dec 6 2007, 357(23):2359-2370.
76. Falutz J., Allas S., Kotler D., Thompson M., Koutkia P., Albu J., et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS Aug 12 2005, 19(12):1279-1287.
77. Data on 52-Week Safety and Efficacy of Tesamorelin, A Growth Hormone-Releasing Factor Analogue, in HIV-Infected Patients with Abdominal Fat Accumulation. 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA 2008, J. Falutz, S. Allas, J.C. Mamputu, D. Kotler, M. Somero, D. Berger (Eds.).
78. Falutz J., Allas S., Mamputu J.C., Potvin D., Kotler D., Somero M., et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS Sep 12 2008, 22(14):1719-1728.
79. Falutz J., Mamputu J.C., Potvin D., Moyle G., Soulban G., Loughrey H., et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J. Clin. Endocrinol. Metab. Sep 2010, 95(9):4291-4304.
80. Stanley T.L., Falutz J., Mamputu J.C., Soulban G., Potvin D., Grinspoon S.K. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS Jun 19 2011, 25(10):1281-1288.
81. Stanley T.L., Falutz J., Marsolais C., Morin J., Soulban G., Mamputu J.C., et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin. Infect. Dis. Jun 2012, 54(11):1642-1651.
82. T.L. Stanley, M.N. Feldpausch, J. Oh, K.L. Branch, H. Lee, M. Torriani, et al., Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial, JAMA 312 (4) (Jul 23-30 2014) 380-389.
83. H. Makimura, M.N. Feldpausch, A.M. Rope, L.C. Hemphill, M. Torriani, H. Lee, et al., Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial, J. Clin. Endocrinol. Metab. 97 (12) (Dec 2012) 4769-4779.
84. M.L. Johnson, L. Pipes, P.P. Veldhuis, L.S. Farhy, R. Nass, M.O. Thorner, et al., AutoDecon: a robust numerical method for the quantification of pulsatile events, Methods Enzymol. 454 (2009) 367-404.